Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs ... for pharmaceutical industry products is evolving at pace with new scientific ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Swiss pharmaceutical giant Novartis raised its 2024 financial targets Tuesday after posting rising sales and margins in the third quarter, thanks in part to increased production of a prostate cancer ...

Currently, the product delivery ... go for $525,000, a list price that “reflects the clinical evidence and benefit” of the treatment. Competitors Gilead’s Tecartus, meanwhile, is priced lower at ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Novartis additionally argued that MSN’s product is not a one-to-one generic ... Entresto will be subject to a 53% cut in its list price for Medicare patients, according to a list of negotiated ...

That list includes heart failure medicine Entresto ... Total revenue jumped by a solid 9% year over year to $12.5 billion. Several Novartis products will remain important growth drivers in ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.